Frindovyx is a drug owned by Avyxa Holdings Llc. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 01, 2035. Details of Frindovyx's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11382923 | Stable liquid formulations of cyclophosphamide and processes to prepare the same |
Dec, 2035
(9 years from now) | Active |
| US10849916 | Stable liquid formulations of cyclophosphamide and its impurities |
Jul, 2035
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Frindovyx's patents.
Latest Legal Activities on Frindovyx's Patents
Given below is the list of recent legal activities going on the following patents of Frindovyx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 May, 2024 | US10849916 |
| Recordation of Patent Grant Mailed | 12 Jul, 2022 | US11382923 |
| Patent Issue Date Used in PTA Calculation | 12 Jul, 2022 | US11382923 |
| Email Notification | 23 Jun, 2022 | US11382923 |
| Issue Notification Mailed | 22 Jun, 2022 | US11382923 |
| Application Is Considered Ready for Issue | 08 Jun, 2022 | US11382923 |
| Dispatch to FDC | 08 Jun, 2022 | US11382923 |
| Issue Fee Payment Verified | 06 Jun, 2022 | US11382923 |
| Issue Fee Payment Received | 06 Jun, 2022 | US11382923 |
| Email Notification | 06 May, 2022 | US11382923 |
US patents provide insights into the exclusivity only within the United States, but
Frindovyx is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Frindovyx's family patents as well as insights into
ongoing legal events
on those patents.
Frindovyx's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Frindovyx's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 01, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Frindovyx Generic API suppliers:
Cyclophosphamide is the generic name for the brand Frindovyx. 19 different companies have already filed for the generic of Frindovyx, with Baxter Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Frindovyx's generic
Alternative Brands for Frindovyx
There are several other brand drugs using the same active ingredient (Cyclophosphamide) as Frindovyx. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Dr Reddys |
| |
| Eugia Pharma Speclts |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cyclophosphamide, Frindovyx's active ingredient. Check the complete list of approved generic manufacturers for Frindovyx
About Frindovyx
Frindovyx is a drug owned by Avyxa Holdings Llc. Frindovyx uses Cyclophosphamide as an active ingredient. Frindovyx was launched by Avyxa in 2023.
Approval Date:
Frindovyx was approved by FDA for market use on 07 June, 2023.
Active Ingredient:
Frindovyx uses Cyclophosphamide as the active ingredient. Check out other Drugs and Companies using Cyclophosphamide ingredient
Dosage:
Frindovyx is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2GM/4ML (500MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 500MG/ML (500MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 1GM/2ML (500MG/ML) | SOLUTION | Prescription | INTRAVENOUS |